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A B S T R A C T
Rationale and objective: Very little is known about the burden of cutaneous melanoma in Central and
South America, despite the existence of a reasonable amount of population-based data. We present data
on melanoma incidence calculated in a standardized way for Central and South America, as well as an
overview of primary and secondary prevention issues in the region.
Methods: Cancer registry data on all incident cases reported in the different registries present in Central
and South America were combined to provide registry-based country estimates of age-standardized, sex-
speciﬁc cutaneous melanoma incidence overall, and by histological subtype and anatomical site. A
literature search provided additional information.
Results: Age-standardized incidence rates were between 1 and 5 per 100,000 and tended to be higher
further away from the equator. Cutaneous melanomas of the acral type, mostly occurring on the lower
limbs, are a distinguishing feature of melanoma in Central and South America in comparison with high-
incidence areas. Several preventive measures, both primary and secondary, are in place, albeit largely
without evaluation.
Conclusion: Due to incomplete registration and different registration practices, reliable and comparable
data on melanoma were difﬁcult to obtain; thus it is likely that the true burden of melanoma in Central
and South America has been underestimated. The different characteristics of the cutaneous melanoma
patient population in terms of anatomical site and histological type distribution imply a need for adapted
primary and secondary prevention measures. The generally high ambient ultraviolet radiation levels
require sufﬁcient sun protection measures.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Worldwide, malignant melanoma accounts for less than 2% of
total cancer cases (excluding non-melanoma skin cancers), and$ This is an Open Access article published under the CC BY-NC-ND 3.0 IGO license
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creativecommons.org/licenses/by-nc-nd/3.0/igo/).although it is not the most common type of skin cancer, it is the
most fatal and causes the largest proportion of skin cancer deaths.
Worldwide, the incidence of melanoma has been increasing
steadily and rapidly [1]. Estimates from GLOBOCAN 2012 show the
global age-standardized incidence rates to be 3.0, varying from
0.3 in South and Central Asia to 35.1 in Australia and New Zealand,
with estimates for Central America (1.6) and South America (2.5)
being close to the global estimate [2]. Poorer survival is generally
reported for melanomas occurring in low- and middle-income
countries compared to high-income countries [3].
There are several histological subtypes of melanoma which
differ in frequency of occurrence by anatomical site, and
potentially by ethnic characteristics of the population [4].
Worldwide, the most frequently occurring histological pattern is
a superﬁcial spreading melanoma, representing the majority
(70–75%) of all melanomas in high-incidence areas; this is followed. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
Table 1
Countries included in the analysis of time trends.
Country Name of registries included Period % of the population covered
Argentina Bahia Blanca 1993–2007 0.8
Brazil Aracaju, Fortaleza, Goiania, Sao Paulo 1997–2006 8.0
Chile Valdivia 1993–2008 2.2
Costa Rica National registry 1985–2007 100.0
E. de Vries et al. / Cancer Epidemiology 44S (2016) S100–S109 S101by nodular melanomas. Lentigo maligna melanomas are almost
exclusively found on sun-damaged skin of the head and neck,
mainly amongst elderly persons. Acral lentiginous melanoma
(ALM) is a relatively rare subtype (worldwide less than 10% of all
melanomas), and is found on the palms of the hands, soles of the
feet, and nail beds. Clinically, they often present late and have a
poorer prognosis than other subtypes [4].
The major external cause of melanoma is exposure to ultraviolet
radiation (UVR) [5], which explains why the incidence of
melanoma is much higher in white than in more pigmented
populations [6]; pigmentations offers some degree of protection
against damage by UVR [7]. A few studies on melanoma across the
South American continent have shown that being of European
ancestry was strongly related to melanoma risk [8–11]. Melanoma
incidence and mortality was very high in populations with a high
proportion of white-skinned people in Brazil [12,13]. The
relationship with UVR is complex and depends on individual
sun-sensitivity reﬂected in phenotypic characteristics such as fair
and red hair, fair skin, light-colored eyes and the presence of
melanocytic nevi (moles) [14–19].
In Latin America ALM is an important type of melanoma, but it is
unclear whether or not it is related to UV exposure. Several case
reports and case–control studies suggest that trauma (deﬁned as
deep penetrative injuries, burns, cuts or thorn pricks) is a risk factor
for melanomas occurring at acral sites or speciﬁcally for ALM [20–
22].Benign nevionthesolesortoeshavealsobeenassociatedwithan
increased risk of hand and foot melanomas and/or ALM [22].Table 2
Incidence and mortality rates (per 100,000) of melanoma among males, all ages.
Incidence 
Period Cases Crude Rate ASR (W) 
Argentinab 2003–2007 382 3.1 3.1 
Belize 2003–2007 . 
Boliviab 2011 8 0.6 0.7 
Brazilb 2003–2007 2194 3.9 4.9 
Chileb 2003–2007 60 2.6 2.6 
Colombiab 2003–2007 253 2.8 3.1 
Costa Rica 1985–1989 84 1.2 1.7 
2003–2007 234 2.2 2.5 
Cubab 2004–2007 39 2.4 1.6 
Ecuadorb 2003–2007 125 2.6 3.2 
El Salvador 1999–2003 47 0.4 0.4 
French Guyanab 2003–2008 13 2.6 3.9 
Guatemala 2003–2007 – 
Mexicob 2006–2010 301 1.8 2.1 
Nicaragua 2003–2007 – 
Panama 2003–2007 – 
Paraguay 2003–2007 – 
Perub 2001–2005 184 2.0 2.2 
Suriname 2003–2007 – 
Uruguay 2005–2007 301 6.3 4.6 
Venezuela 2003–2007 – 
ASR (W), age-standardized (World population) rate per 100,000; M:I, mortality-to-inci
a National mortality.
b Incidence rates were estimated using data from regional cancer registries.
c Rank across cancer types, based on highest ASR excluding: all sites but C44 and alIn this paper we aim to provide a clearer picture of melanoma in
Central and South America, including information on incidence by
anatomical site and histological subtype and mortality, and we
discuss national initiatives for primary or secondary prevention of
skin cancer that are in place in the various countries of the region.
2. Methods
We included only cutaneous melanomas for this study. Ocular
and mucosal melanomas are very rare cancers which constitute
separate entities in the third revision of the International
Classiﬁcation of Diseases for Oncology (ICD-O3) and they are
not considered in this paper (uveal or ocular melanomas ICD-
O3C69.3 and C69.4; mucosal melanomas, all cancer sites except
C7–C8, C22, C25, C37–C50, C54, C55.9, C56, C57.0–57.9, C58.9,
C60.0–C66.9, C68.1, C68.9, C69.1–C80.9).
The data sources and methods are described in detail in another
article in this issue. In brief, we obtained regional- and national-
level incidence data from 48 population-based cancer registries in
13 countries and cancer deaths from the World Health Organiza-
tion mortality database for 18 countries. We estimated age-
standardized incidence (ASR) and mortality (ASMR) rates per
100,000 person-years using the direct method and the world
standard population [23]. We estimated national ASRs by
aggregating the data from the available cancer registries using a
weighted average of local rates. To describe incidence and
mortality time trends, we calculated the estimated annual percentMortalitya
Rankc Deaths Crude Rate ASR (W) Rank z M:Ia
18 1271 1.3 1.2 17 0.43
. 1 0.1 0.4 15
13 . .
15 3303 0.7 0.8 16 0.18
19 419 1.0 1.0 18 0.41
15 479 0.5 0.6 17 0.16
19 29 0.4 0.6 11 0.34
16 89 0.8 0.9 17 0.38
19 141 0.6 0.4 18 0.26
15 119 0.4 0.4 17 0.13
14 4 0.0 0.0 19 0.08
16 – –
– 95 0.3 0.5 14
14 1258 0.5 0.7 18 0.26
– 14 0.1 0.2 19
– 39 0.5 0.5 16
– 65 0.4 0.7 14
17 240 0.4 0.5 16 0.18
– 3 0.2 0.3 17
16 83 1.7 1.2 17 0.27
– 251 0.4 0.5 17
dence ratio.
l sites.
Table 3
Incidence and mortality rates (per 100,000) of melanoma among females, all ages.
Incidence Mortalitya
Period Cases Crude Rate ASR (W) Rankc Deaths Crude Rate ASR (W) Rank z M:Ia
Argentinab 2003–2007 410 3.2 2.8 17 960 1.0 0.7 19 0.31
Belize 2003–2007 . . 1 0.1 0.3 19
Boliviab 2011 10 0.7 0.7 16 . .
Brazilb 2003–2007 2398 3.9 3.8 15 2566 0.5 0.5 18 0.14
Chileb 2003–2007 52 2.3 2.1 19 350 0.8 0.7 18 0.36
Colombiab 2003–2007 306 3.0 2.9 17 460 0.4 0.5 21 0.14
Costa Rica 1985–1989 74 1.1 1.6 19 19 0.3 0.4 13 0.25
2003–2007 221 2.1 2.2 17 53 0.5 0.5 21 0.24
Cubab 2004–2007 41 2.5 1.8 18 97 0.4 0.3 22 0.17
Ecuadorb 2003–2007 168 3.3 3.4 16 93 0.3 0.3 19 0.09
El Salvadorb 1999–2003 34 0.2 0.3 20 4 0.0 0.0 20 0.11
French Guyanab 2003–2008 8 1.6 2.3 18 – –
Guatemala 2003–2007 – – 59 0.2 0.3 17
Mexicob 2006–2010 345 2.0 2.0 14 1084 0.4 0.5 20 0.19
Nicaragua 2003–2007 – – 16 0.1 0.2 21
Panama 2003–2007 – – 26 0.3 0.3 19
Paraguay 2003–2007 – – 41 0.3 0.3 18
Perub 2001–2005 200 2.1 2.1 18 190 0.3 0.3 19 0.14
Suriname 2003–2007 . . 2 0.2 0.1 21
Uruguay 2005–2007 277 5.4 3.6 16 46 0.9 0.6 19 0.17
Venezuela 2003–2007 – – 208 0.3 0.4 21
ASR (W), age-standardized (World population) rate per 100,000; M:I, mortality-to-incidence ratio.
a National mortality.
b Incidence rates were estimated using data from regional cancer registries.
c Rank across cancer types, based on highest ASR excluding: all sites but C44 and all sites.
S102 E. de Vries et al. / Cancer Epidemiology 44S (2016) S100–S109change (EAPC) using the method proposed by Esteve [24]. Trends
in incidence and EAPCs were estimated for only four countries
(Table 1) that provided written consent for the use of their data, or
that submitted new data for 10 years, and we matched mortality
data to the same time period to generate time trends and EAPC. All
of the EAPCs were tested for equality to zero by using the
corresponding standard errors. We considered EAPCs statistically
signiﬁcant if the P-value was 0.05. We conducted the data
analysis in Stata version 12.1 (StataCorp).
We also considered information by anatomical site and
histological subtype as coded in ICD-O-3. Unfortunately,0
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Fig. 1. Age-standardized incidence rate (per 100,000) of melanoma by latitude, most 
correlation index: males 0.623, females 0.615, both two-tailed P < 0.001, weighted for information on histological subtype from most Latin American
registries was incomplete, and therefore we decided to include
for this analysis only registries which qualiﬁed for publication in
CI5 volume X [25]. Anatomical site was grouped as “upper limbs”,
“lower limbs”, “head and neck”, “trunk” and “other and not
otherwise speciﬁed”. Correlations between age-standardized
incidence rates and latitude, weighted by registry population
size, were calculated using Pearson correlation index using SPSS
version 19.
A non-systematic search in Pubmed, SCieLo and Google was
performed regarding legislation and actions on sun protection0 30 40 50 60 70
grees South)
recent periods per registry. Red squares: males, blue diamonds, females. Pearson
population size of the registries.
E. de Vries et al. / Cancer Epidemiology 44S (2016) S100–S109 S103measures in the region, given the causative relationship between
melanoma and UVR.
3. Results
3.1. Age-standardized incidence and mortality rates
Incidence of melanoma in Central and South America was
generally low, but showed substantial geographic variation
(Tables 2 and 3). In Central and South America as a whole, malignant
melanomaaccountedforabout1.4%ofall invasivecancers(excluding
non-melanoma skin cancers) [25]. Incidence rates were, on average,
lower in Central than in South American countries. Melanoma
ranked between the 13th (Bolivia, males) and the 20th (El Salvador,
females) of the most commonly diagnosed cancers (Tables 2 and 3).
Estimated age-standardized incidence rates (ASRs) ranged from less
than 1.0 (Bolivia and El Salvador, among both males and females) to
almost 5.0 (Brazil, males) per 100,000 person-years. Correlating the
ASRs of the cancer registries by their latitude showed clear
correlation with latitude for both males and females, with rates
increasing from north to south (Pearson correlation index: males
0.623, females 0.615, both two-tailed P < 0.001, weighted for
population size of the registries) (Fig. 1).
Age-standardized mortality rates were generally well under
1.0 per 100,000 person-years, with the exception of males in
Argentina, Chile, and Uruguay (ranges between 1.0 and 1.2 per
100,000 person-years). Although incidence rates were similar
between sexes, melanoma mortality rates were lower among
females than males in all countries (Tables 2 and 3).
Mortality-to-incidence (M:I) ratios varied greatly over the region,
ranging between 8% (El Salvador) and 43% (Argentina) for males and
9% (Ecuador) and 36% (Chile) for females (Tables 2 and 3)..1
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Fig. 2. Trends in melanoma incidence and 3.2. Time trends
In Argentina, Brazil, Chile and Costa Rica for the period 1997–
2007, rates showed stable incidence and mortality patterns, with
the exception of Chilean males, for whom increases in incidence of
10.2% annually were observed, accompanied by a non-statistically
signiﬁcant decline in mortality (Figs. 2 and 3). Costa Rica provided
data for the period 1985–2007, allowing for longer-term compar-
isons. Male age-standardized incidence rates in Costa Rica almost
doubled from 1.3 in the period 1985–1989 to 2.5 in 2003–2007, and
female age-standardized incidence more than doubled – from
0.9 to 2.2 per 100,000 person-years – during this period, although
this trend did not reach statistical signiﬁcance.
3.3. Distribution by histological subtype and anatomical site
Unfortunately, information on histological subtypes from most
Latin American registries was incomplete. Table 4 shows the
distribution by histological subtype for the registries which
published in CI5-X. Although at least 47% of the melanomas did
not have information by histological subtype, the proportion of
acral lentiginous melanomas (ALMs) in registries with information
on subtype for around 50% of melanomas was 10–15%, with the
exception of Aracaju, Brazil (6%). Even in cancer registries with
substantially lower proportions of melanomas with information by
subtype, available estimates of 4–9% ALM were still observed in
many cancer registries.
Table 5 shows the proportions and age-standardized incidence
rates by anatomical site and country. Although a substantial
proportion were deﬁned as “melanoma not otherwise speciﬁed”
(NOS), some general patterns become clear by inspecting the
proportions: men tended to have a higher proportion of melano-
mas on the trunk than women, and women have higher
proportions on the upper and lower limbs. There were, however,
clear differences within the region in the sex-speciﬁc site.1
1
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1985 19 90 1995 200 0 200 5 201 0
Females
gregated  data from region al cancer registries
WESS=0.5) smoothe d tren d
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Fig. 3. Estimated annual percentage change in age-standardized incidence and mortality rates (per 100,000) of melanoma by sex.
S104 E. de Vries et al. / Cancer Epidemiology 44S (2016) S100–S109distribution. With the exception of French Guyana, less than 25% of
male melanomas occurred on the trunk. The proportion of
melanomas occurring on the lower limbs amongst males was 7%
in Uruguay, 8% in Argentina, 13% in Cuba and 14% in Brazil.Table 4
Proportion of cases with information on histological subtype, and distribution of his
Continents Vol. X. The reporting period is the same per registry as reported in Tables 2
Melanoma
NOS Nodular Lentigo m
% (n) % (n) % (n) 
Registries with <60% NOS
Brazil Aracaju 49 (62) 19 (24) 5 (6) 
Chile Valdivia 51 (76) 20 (30) 7 (10) 
Colombia Bucaramanga 47 (46) 16 (15) 9 (9) 
Cali 52 (182) 18 (62) 7 (23) 
Costa Rica National Registry 48 (702) 18 (265) 7 (107) 
Registries with >60% NOS
Argentina Bahia Blanca 76 (128) 15 (25) 2 (3) 
Cordoba 82 (166) 7 (15) 6 (12) 
Mendoza 67 (187) 21 (58) 2 (5) 
Tierra del Fuego 63 (10) 6 (1) – 
Brazil Belo Horizonte 76 (159) 9 (18) 4 (9) 
Cuiaba 94 (63) 5 (3) 
Fortaleza 98 (464) 1 (4) 1 (5) 
Goiania 86 (568) 6 (41) 2 (16) 
Sao Paolo 90 (7075) 5 (399) 3 (193) 
Chile Antofagasta 63 (34) 11 (6) 9 (5) 
Colombia Manizales 84 (53) 6 (4) 5 (3) 
Pasto 80 (34) 2 (1) 4 (2) 
Cuba Villa Clara 99 (108) 1 (1) – 
Ecuador Cuenca 84 (42) 8 (4) – 
Quito 77 (188) 14 (35) 1 (3) 
Uruguay National Registry 91 (525) 6 (32) 2 (14) 
NOS, not otherwise speciﬁed.3.4. Public health policies and prevention activities
Several Latin American countries have implemented recom-
mendations or legislations with regard to protection against UVR
in order to prevent skin cancer. In Chile employers are obliged by
law to take necessary measures to effectively protect workers whotological subtypes among cancer registries included in Cancer Incidence in Five
 and 3 .
aligna Superﬁcial spreading Acral lentiginous Other types
% (n) % (n) % (n)
11 (14) 6 (7) 10 (13)
7 (11) 12 (17) 3 (4)
14 (14) 10 (10) 3 (3)
7 (26) 15 (54) 2 (6)
14 (208) 10 (139) 2 (30)
0.6 (1) 0.6 (1) 6 (10)
4 (8) – 0.5 (1)
5 (13) 2 (5) 4 (10)
13 (2) 6 (1) 13 (2)
6 (12) 4 (9) 0.5 (1)
2 (1)
0.2 (1) – 0.2 (1)
4 (24) 2 (10) 1 (5)
0.5 (32) 1 (108) 0.5 (35)
4 (2) 4 (2) 9 (5)
2 (1) 3 (2) –
– 9 (4) 4 (2)
– – –
2 (1) – 6 (3)
– 4 (10) 3 (7)
0.5 (3) 0.2 (1) 0.5 (3)
Table 5
Proportions and age-standardized incidence rates (per 100,000) by sex. The reporting period is the same per registry as reported in Tables 2 and 3.
Country Head & neck Trunk Arm, shoulder Leg, hip Overlapping NOS
% (ASR) % (ASR) % (ASR) % (ASR) % (ASR) % (ASR)
Males
All 17.9 (0.56) 22.7 (0.65) 10.4 (0.32) 17.4 (0.56) 0.3 (0.01) 31.2 (1.0)
Argentina1 10.8 (0.32) 14.3 (0.45) 8.2 (0.27) 8.0 (0.24) 0.4 (0.01) 58.4 (1.75)
Bolivia1 37.5 (0.28) – 0 (–) 50 (0.36) – 12.5 (0.09)
Brazil1 18.0 (0.77) 25.0 (0.91) 11.3 (0.44) 13.9 (0.58) 0.2 (0.01) 31.7 (1.36)
Chile1 31.7 (0.78) 18.3 (0.48) 6.70 (0.19) 21.7 (0.55) – 21.7 (0.58)
Colombia1 25.3 (0.78) 21.7 (0.62) 9.50 (0.29) 31.6 (0.99) 0 (0) 11.9 (0.36)
Costa Rica 20.0 (0.39) 25.1 (0.52) 10.3 (0.21) 34.7 (0.70) 0.7 (0.01) 9.10 (0.19)
Cuba1 18.3 (0.25) 5.00 (0.08) 6.70 (0.11) 13.3 (0.18) – 56.7 (0.85)
Ecuador1 24.0 (0.69) 16.8 (0.53) 8.80 (0.28) 33.6 (1.05) 0.8 (0.04) 16.0 (0.52)
El Salvador1 18.5 (0.07) 0 (–) 1.90 (0.01) 57.4 (0.20) 1.9 (0.01) 20.4 (0.09)
French Guyana1 26.7 (0.95) 26.7 (0.74) 26.7 (0.86) 20.0 (0.92) – –
Mexico1 17.9 (0.39) 17.3 (0.34) 8.30 (0.16) 24.0 (0.51) – 32.5 (0.59)
Peru1 16.8 (0.35) 11.7 (0.21) 7.30 (0.15) 41.9 (0.84) – 22.3 (0.44)
Uruguay 11.3 (0.51) 17.6 (0.84) 8.00 (0.39) 7.3 (0.31) 0.7 (0.03) 55.1 (2.52)
Females
All 14.2 (0.37) 16.3 (0.41) 13.7 (0.36) 26.2 (0.70) 0.4 (0.01) 29.2 (0.79)
Argentina1 10.6 (0.25) 11.8 (0.35) 7.80 (0.22) 17.3 (0.47) 0.2 (0.01) 52.4 (1.39)
Bolivia1 40.0 (0.28) – 30.0 (0.28) 20.0 (0.09) – 10.0 (0.07)
Brazil1 14.2 (0.46) 18.1 (0.55) 13.9 (0.43) 23.7 (0.76) 0.4 (0.01) 29.8 (1.01)
Chile1 19.2 (0.40) 17.3 (0.35) 19.2 (0.41) 19.2 (0.40) – 25.0 (0.53)
Colombia1 21.9 (0.63) 10.1 (0.30) 13.4 (0.40) 38.6 (1.07) 0.7 (0.02) 15.4 (0.45)
Costa Rica 14.5 (0.26) 14.8 (0.25) 18.5 (0.35) 42.8 (0.76) 0.9 (0.02) 8.40 (0.16)
Cuba1 14.3 (0.15) 8.20 (0.12) 20.4 (0.25) 10.2 (0.12) – 46.9 (0.60)
Ecuador1 21.4 (0.69) 7.10 (0.24) 13.7 (0.49) 46.4 (1.56) 0 (0) 11.3 (0.34)
El Salvador1 2.20 (0.00) 20.0 (0.06) 15.6 (0.05) 44.4 (0.11) 0 (0) 17.8 (0.05)
French Guyana1 0 (–) 20.0 (0.25) 30.0 (0.65) 50.0 (1.27) – –
Mexico1 14.4 (0.28) 12.9 (0.25) 12.9 (0.28) 28.0 (0.57) – 31.8 (0.53)
Peru1 10.6 (0.20) 9.60 (0.17) 13.6 (0.29) 42.4 (0.84) – 23.7 (0.44)
Uruguay 11.2 (0.33) 14.4 (0.62) 7.20 (0.29) 18.4 (0.72) 0 (0) 48.7 (1.67)
NOS, not otherwise speciﬁed.
ASR, age-standardized (Segi world standard population) incidence rate per 100,000.
1 Estimates based on weighted average of regional registries, no national coverage.
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that tax revenues from products such as sunscreens are transferred
to the national cancer hospital to promote campaigns on the risks
of unprotected exposure to UVR. In addition, the Ministries of
Health and Education implement policies against skin cancer [27].
In Peru, legislation regulates protection of children in schools by
limiting activities involving unprotected UVR exposure, regulating
school uniforms, and including education on the risks of UVR
exposure as obligatory in the educational program. Employers
must provide their UVR-exposed employees with sunscreens and
adequate protective clothing. In parks and other public outdoor
areas, signs must be put in place stating the risks of prolonged UVR
exposure [28,29].
Although there is no speciﬁc legislation, efforts to prevent skin
cancer have been put in place with national awareness campaigns
in Argentina, Cuba, Panama, Peru and Uruguay, and regional
campaigns in Bolivia, Colombia, Ecuador, and Paraguay [29]. In
Costa Rica the national cancer control plan includes, among other
things, reduction of sun exposure [30]. Similarly, in the national
cancer control plan of Honduras the promotion of awareness
campaigns to control skin cancer has been included [31].
In several countries of the region, speciﬁc “melanoma days”
have been organized with the aim of calling attention to the skin
cancer epidemic, providing information about risk factors and
prevention measures, and about signs and symptoms of melano-
mas to enhance early detection. National or regional awareness
campaigns are organized in almost all countries of South America
and consist of providing information on risk factors, early signs
(sometimes but not always adapted to the characteristics of the
region) and in some cases providing “melanoma screening days”
during which dermatologists offer their services, usually free ofcharge, to screen the participating population [32–38]. New
prevention campaigns for early detection of skin cancer are arising
in Guatemala and Mexico (Mexico City) [39].
4. Discussion
This study shows that melanoma is still a relatively rare cancer
diagnosis in Central and South America. Incidence rates vary
between 1 and 5 per 100,000, being considerably lower than
observed rates among white populations in the world’s highest
incidence areas such as Australia (ASR: males 40.5, females 33.1)
[2]. The observed differences in incidence rates, with lowest rates
in Central America, may be due partly to the higher proportion of
indigenous populations in these countries, with more pigmented
skin and therefore lower risk of melanoma [40]. However, Ecuador
has much higher incidence rates, also with a high proportion of
indigenous inhabitants [41]. Bolivia has a large percentage of
indigenous peoples, but an extremely low incidence rate (0.7 for
both sexes), which may also be due to low coverage of the cancer
registry (covering only 1 year of data collection at the moment).
The population of Brazil is largely mestizo, and perhaps the lower
skin pigmentation combined with a strong skin tanning culture
explains the relatively high incidence rates of melanoma in this
country [41,42].
In general, the amount of UV radiation reaching the earth’s
surface decreases with distance from the equator. In the Southern
Hemisphere, however, the “hole” in the ozone layer modiﬁes this
general rule; very high UVR levels were observed in the south of
South America [43,44], coinciding with the observed higher
incidence rates further away from the equator in South America.
Supplemental Table 1 provides UV index measurements for the
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equator, although complex migration patterns have distorted the
original skin pigmentation gradient of the continent [45,46]. In
Punto Arenas, the southernmost city of Chile, the numbers and
incidence of skin cancers were found to be increasing [47], and a
study on melanoma mortality in Brazil showed mortality rates in
the south of Brazil – with >83% of the population being white – to
be 7 times higher than in the northern region, where >70% of the
population was non-white [12]. Another geographical factor
determining UV exposure is altitude: each 300 m increase in
altitude increases the sun-burning effectiveness of sunlight by
about 4% [48]. Correa et al. reported that South American cities in
high-altitude areas are at risk of dangerous levels of UV radiation
[44].
M:I ratios varied substantially across the region, and although
they depend on completeness of data, a very low M:I ratio
generally implies less aggressive disease (better survival) and a
high M:I a more aggressive disease (worse survival). In almost all
countries, M:I ratios were lower for women than for men, in line
with observations indicating better prognosis for women, for so far
unknown reasons [49–53]. Relatively high M:I ratios also indicate a
late stage at diagnosis. Indeed, a Colombian case series reported
high proportions of advanced disease at the time of diagnosis
(23.4% diagnosed in stage III, 46.9% in stage IV; 98% had Breslow
thickness 2.1 mm), and 22% of melanomas were ulcerated [54].
There are very few reports of melanoma survival in Central and
South America. One hospital-based study from Rio de Janeiro,
Brazil [53], reports overall 5-year survival of 67.0% and conﬁrms
the large gender differences in melanoma survival observed in
other continents—hazard ratio (HR) 1.91 for males versus females –
and also highlights large differences in survival by educational
level, varying from 50.8% for illiterate patients up to 76.5% for
patients with >12 years of education [53].
The poor correlation between incidence and mortality is very
common, also in high-incidence (generally more developed)
countries. This may be due to a high awareness in the very-
high-incidence countries, resulting in early diagnosis and quite
good prognosis, but also potential over-diagnosis. On the contrary,
in the relatively low-incidence and low-mortality countries, the
risk of under-diagnosis is more present. Therefore, the variation in
incidence versus mortality reﬂects what we expected. Approxi-
mately 80–100% of the cases diagnosed in the region were
microscopically veriﬁed, which is higher than the 20–30% reported
in the United States [25], indicating an over-reliance on the
pathology laboratory as a source of information [55] and implying
that indeed there is a certain degree of under-ascertainment of
cases.
The observed overall stable trends during 1997–2007 for
Argentina, Brazil, Chile and Costa Rica coincide with local reports
from neighboring countries; time trends of melanoma incidence
from Colombia showed no changes over time: estimated annual
percentage change (EAPC) Cali 1962–2007 females 1.6% (95%
conﬁdence interval 0.8–2.3); Pasto 1998–2007 males EAPC 0.67%,
females EAPC 0.03% [56,57]. However, time trends of melanoma
mortality over a longer period (1980–2005) in Brazil showed stable
mortality trends in males under the age of 50 years, with
signiﬁcant increases (1.6% annually) for females in this age group,
and signiﬁcant increases observed for both sexes in the age group
50–69 years (EAPC 1.6% and 1.4% for males and females
respectively) and in the age group of 70 years (EAPC 2.8% for
males, 2.3% for females) [12].
Compared to Caucasians, more pigmented populations tend to
have (proportionally) more ALM, occurring on the soles of the feet
and palms of the hands [6,58]. This may explain why the observed
proportions of ALM in Latin American populations, although
underestimated because of the high proportion of subtype “notspeciﬁed”, were substantially higher in our study than in
populations with high melanoma incidence rates, where pro-
portions of ALM are around 1% or lower [58,59]. Published
estimates of proportions of ALM among Latin American or
Hispanic populations vary widely, for instance 4–6% for Hispanics
in the USA [58,60], 6% in the Argentinean Melanoma Registry
(RAMC) (with 33% not otherwise speciﬁed) [61], 19% for Chile
[62], and >42% in Colombia (the latter based on data from hospital
registries) [63].
The observed sex-speciﬁc site distribution, with more melano-
mas on the trunk in males and on the limbs in females, is similar to
observations from high-incidence areas [59,64–67]. However,
male trunk melanomas are less predominant in Latin America
(less than 25% in virtually all countries) than in predominantly
Caucasian populations, coinciding with observations from the USA
where 25% of melanomas amongst Hispanic males occurred on the
trunk, versus 33% of melanomas in non-Hispanic white popula-
tions [68]. This lower proportion of trunk melanomas is
compensated by a higher proportion (above 30%) of melanomas
located on the lower limbs amongst males in Central America and
the northern part of South America. This ﬁnding is in accordance
with observations from Chile, where around 33% of melanomas
were found on the legs or feet, in both sexes [62], and with reports
from California, where 6% of melanomas occurring in Hispanic
males were ALM (mostly occurring on the feet) versus 0.6% among
non-Hispanic whites [60]. More southern countries in South
America followed a more “Western” pattern in terms of anatomical
site distribution: the proportion of melanomas occurring on the
lower limbs amongst males was 7% in Uruguay, 8% in Argentina and
14% in Brazil, similar to the proportions on the lower legs amongst
men in European countries and Canada [59,65,67].
Melanoma incidence is low, but mortality relatively high in
Central and South America. This, and the high M:I ratios, ﬁt
worldwide patterns of better survival in high-incidence areas
[69]. This pattern is thought to be related to low awareness in the
population and among medical professionals, because of the low
proportion of people developing melanoma. Many general
physicians do not possess the knowledge and skills to correctly
diagnose skin cancers [70], and for the general public this is even
more difﬁcult. Awareness campaigns on primary prevention
messages as well as warning signs for skin cancer, and urging
people to consult a physician when speciﬁc changes, spots or
moles are observed on the skin, may help in lowering the stage of
melanoma at diagnosis and thereby improving survival [71,72].
Such campaigns are already organized in certain regions, but their
dissemination and visibility can certainly be improved.
It is promising that data from participants in the Peruvian skin
cancer screening day showed that sunscreen use increased from
22.5% of participants in 2005 to 31.4% in 2011 [37]. A study performed
among physical education teachers in Mexico, Honduras and Costa
Rica showed that exposure to UVR could be reduced by adapting the
hours of the classes and requiring the use of sports clothes with long
sleeves and long trousers [73]. The US Surgeon General has recently
issued a very detailed call for skin cancer prevention; this contains
very concrete steps and recommendations and may be useful for
prevention purposes in Central and South America [74]. It is
important to provide protection for outdoor workers, particularly in
regions with high ambient UVR. However, despite the existence of
laws protecting workers from exposure to UVR, a large proportion (in
many countries in the region more than one third) of the population
are informal workers and will usually be unprotected [75]. Informal
work is particularly common in outdoor occupations: e.g. farmers,
construction workers, street sellers.
Unfortunately, no primary prevention messages can be
formulated for ALM, because of the lack of scientiﬁc knowledge
regarding its risk factors. However, in the absence of effective
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detection (secondary prevention) is relevant to reducing mortality
from this form of melanoma in the region. The many screening day
initiatives in the region may provide a positive contribution to
early detection. It is very important for campaigns in the region to
adapt the message from similar initiatives in high-incidence
regions, stressing the importance of checking the soles of the feet
and the palms of the hands, as well as the nails.
5. Conclusion
Melanoma remains a relatively rare diagnosis in Central and
South America and occurs almost equally among males and
females. Evaluation of incidence rates of melanoma by speciﬁc
histological subtype was hindered by the large percentage of
tumors with unspeciﬁed histology. The predominant localization
of melanomas observed in males (trunk) and females (upper and
lower limbs) in Central and South America (excluding French
Guyana) was similar to the patterns reported in other countries,
but in many countries of the region the proportion of melanomas
on the lower limbs is high, coinciding with a relatively high
proportions of acral lentiginous melanomas. In countries with a
large part of the population being of European descent – such as
Argentina, Brazil, and Uruguay – body-site distribution of
melanoma appears to be similar to that in North America and
Europe.
Due to incomplete registration and different registration
practices, reliable and comparable data on melanoma were
difﬁcult to obtain; thus it is likely that the true burden of
melanoma in the Central and South America has been under-
estimated, as is also indicated by the high proportion of
microscopically veriﬁed cases. This may inhibit the willingness
of governments to respond in a timely fashion with public health
initiatives. Improved ascertainment of cases and changes in the
types of cases being registered must be taken into account in order
to determine the real burden of this malignancy in the region. We
recommend regional population-based cancer registries to publish
their more detailed data on this and other infrequent cancers in
their population, with details on exact localization and morpholo-
gy; this would greatly aid the interpretation and investigation of
the characteristics of the melanoma burden in Central and South
America and would be valuable information for primary and
secondary intervention measures.
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